Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.

Subscribe for Email Updates

MAPS is recruiting participants for Phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD.

Apply Now

Learn more:

Watch MAPS Founder Rick Doblin, Ph.D., present the first official TED Talk about psychedelics, filmed on the main stage at TED2019.


PRESS RELEASE: Psychopharmacology Publishes Combined Analysis of Phase 2 Clinical Trials of MDMA-Assisted Psychotherapy for PTSD

This paper is the most comprehensive analysis yet published of research into the efficacy and safety of MDMA-assisted psychotherapy for PTSD

MAPS Newsletter: October 2019

This month's Newsletter includes research news, upcoming events, and more!

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline

A new publication from the peer-reviewed Frontiers in Psychiatry journal compares data from Phase 2 clinical trials of MDMA-assisted psychotherapy for PTSD to research on medications currently approved to treat PTSD.

MAPS Receives $4,140,000 Grant from Psychedelic Science Funders Collaborative (PSFC)

The generosity of our supporters continues to humble us

MAPS Bulletin Summer 2019: Research Edition

This edition features over 5 original articles and psychedelic research news updates

Participate in Research

MAPS sponsors clinical trials around the world that offer volunteers the opportunity to participate in our research studies

Our Research

MDMA-Assisted Psychotherapy

Our highest priority project is funding clinical trials of 3,4-methylenedioxymethamphetamine (MDMA) as a tool to assist psychotherapy for the treatment of posttraumatic stress disorder (PTSD).

We have also sponsored completed clinical trials of MDMA-assisted psychotherapy for anxiety associated with life-threatening illness, and MDMA-assisted psychotherapy for social anxiety in autistic adults.

MDMA website

lsd block website

LSD-Assisted Psychotherapy

MAPS has completed the first double-blind, placebo-controlled study of the therapeutic use of LSD in human beings since the early 1970s.

Ibogaine Therapy for Drug Addiction

We have completed studies of the long-term effects of ibogaine treatment on patients undergoing therapy at independent ibogaine treatment centers in Mexico and New Zealand.

ibogaine bottle website

ayahuasca vine website

Ayahuasca-Assisted Treatment

MAPS supports research into the safety and effectiveness of ayahuasca-assisted treatment for drug addiction and PTSD. We also support conferences, meetings, and publications about the scientific, therapeutic, sustainable, and spiritual uses of ayahuasca.

Medical Marijuana

MAPS has completed the first-ever clinical trial of smoked marijuana for symptoms of posttraumatic stress disorder (PTSD) in veterans of war.

marijuana website

Our Values


Information is shared openly and clearly. Communications are respectful, honest, and forthright.

Passion and Perseverance

We persist in the face of challenges. We have a sense of urgency about our work, and know that it's a long-term effort.

Intelligent Risk

Our decisions are informed by research. We try new things and learn from our mistakes.

Trust and Accountability

We value integrity and honesty, and embrace high standards.